Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Tillotts Pharma AG Stories

2011-09-10 07:00:00

Augurix SA (âœAugurixâ) and Tillotts Pharma AG (âœTillottsâ) are pleased to announce that they have entered into a commercialization agreement for Simtomax®, a rapid point-of-care diagnostic test for celiac disease. Monthey/Rheinfelden, Switzerland (PRWEB) September 10, 2011 Augurix SA (âœAugurixâ) and Tillotts Pharma AG (âœTillottsâ)...

2011-07-06 07:46:00

EAST RUTHERFORD, N.J. and RHEINFELDEN, Switzerland, July 6, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") and Tillotts Pharma AG ("Tillotts") are pleased to announce they have entered into a Development and Commercialization Agreement for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of Inflammatory Bowel Disease (IBD). "This deal, which gives Tillotts worldwide access to an exciting proprietary 5-ASA-based technology, is an additional...